PBK and neoplasm: Furthermore, [18F] FE-OTS964 has been produced from OTS964; this preclinical drug specifically binds to TOPK, and test results have revealed that it reduces tumor uptake ratio from 3.06 ± 0.30% ID/cc to 1.40 ± 0.42% ID/cc, which was reduced in animals co-injected with an excess blocking dose of OTS541.